Clinical Trial Update: IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic [Phase 2]

View source ↗

Summary

Phase 2 trial in relapsed and refractory multiple myeloma evaluating IPD characterized by adverse prognostic genomic abnormalities; the study status is terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Intergroupe Francophone du Myelome | Conditions: Multiple Myeloma, Relapsed and Refractory Multiple Myeloma | Phase 2 | Status: TERMINATED